Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6086351 | Best Practice & Research Clinical Gastroenterology | 2014 | 10 Pages |
Abstract
Rapid advances in our understanding of inflammatory bowel diseases have resulted from the synthesis of data from experimental and genetic studies. These have suggested a wide range of potential immunological targets with both local and systemic scope. Drugs to several of these targets have now reached phase I/II studies, and are discussed in the context of their scientific rationale. However, despite the advent of new classes of therapeutics targeting cellular trafficking and intracellular mediators of cytokine signalling, the armamentarium of effective therapeutics remains sparse. Only with more detailed experimental medicine studies will this imbalance be resolved.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
Tim (Wellcome Trust Clinical Fellow and Clinical Lecturer, Gastroenterology, University of Cambridge),